← All trials
NCT03627390
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 19, 2014
- Primary completion
- Mar 4, 2016
- Completion date
- Mar 4, 2016
- First posted
- Aug 13, 2018
- Last posted
- Nov 15, 2018
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Meabco A/SLead sponsor
- Menoufia UniversityOverall official - principal investigator
- Norwegian University of Life SciencesCollaborator
- Meddoc ASCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.